Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Biomea Fusion Inc. Common Stock
BMEA | US
1.37
USD-0.02
-1.44%
BMEA | US
About Biomea Fusion Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
1.37
Open
1.40
High
1.44
Low
1.35
Biomea Fusion Inc. a clinical-stage biopharmaceutical company focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219 an orally bioavailable potent and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion Inc. was incorporated in 2017 and is headquartered in Redwood City California.
View LessBMEA | US
Risk
71.2
Sharpe
-0.08
Luna's Score
42/100
Recommendation
Sell
Luna says (BMEA | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
57.4%1 month
71.2%3 months
100.5%6 months
93.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.98
Debt to equity
0.10
Debt to assets
0.08
Ent. to EBITDA
-3.75
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-146.72M
MarketCap
49.61M
MarketCap(USD)
49.61M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-85.09
Short ratio
9.35
Short perc.
35.67
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.25
Range1M
0.52
Range3M
1.17
Volumes: Market Activity
Rel. volume
0.74
Price X volume
1.21M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.75 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.98 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 100.54 | - | Riskier |
| Debt to Equity | 0.10 | -1.23 | Expensive |
| Debt to Assets | 0.08 | 0.25 | Cheaper |
| Market Cap | 49.61M | - | Emerging |
